The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site.

All material subject to strictly enforced copyright laws. © 2020 Euromoney, a part of the Euromoney Institutional Investor PLC.
Capital Markets

Taiwan’s capital markets malaise

A falling number of corporates are choosing to list on the Taiwan Stock Exchange. Given the dire after-market performance of Aslan Pharmaceuticals, it is not hard to see why.

taipei cityscape clouds-600
Taipei is not the place you go to complete big equity capital markets transactions,
wherever you come from

When Aslan Pharmaceuticals cast around for the right place to sell shares earlier this year, it did not choose Hong Kong, nor its hometown of Singapore, nor even mainland China’s two leading bourses, but Taiwan.

Aslan’s chief executive Carl Firth, a former head of Asia healthcare investment banking at Bank of America Merrill Lynch, was convinced it was the right decision. The firm’s lack of profitability – it posted a small pre-tax loss in 2016 – had ruled out Hong Kong, while the US exchanges were deemed too volatile.

Take out a complimentary trial

Take out a 7 day trial to gain unlimited access to Euromoney.com and Asiamoney.com analysis and receive expertly-curated updates direct to your inbox.

 

Already a user?

Login now

 

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree